Related Posts:
Novo Nordisk’s Ozempic receives EU recommendation for peripheral arterial disease
June 23, 2025
Pending approval from the European Commission, Novo Nordisk's Ozempic is set to have the most comprehensive label in its class.
Read more →
Novo Nordisk’s phase 3b trial shows promising results for haemophilia A treatment
June 22, 2025
Novo Nordisk has released findings from the phase 3b FRONTIER5 trial, which demonstrate that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment is well-tolerated in adults and adolescents with haemophilia A....
Read more →
Novo Nordisk’s new obesity drug shows promise in recent clinical trial
June 22, 2025
Today, the New England Journal of Medicine published findings from Novo Nordisk's phase 3 REDEFINE 1 trial.
Read more →
Higher dose Wegovy shows promise for significant weight loss
June 20, 2025
Novo Nordisk has presented findings from the phase 3b STEP UP trial at the American Diabetes Association (ADA) Scientific Sessions in Chicago.
Read more →
Novo Nordisk presents amycretin data at ADA Scientific Sessions
June 20, 2025
Novo Nordisk has published data in The Lancet and presented findings at the American Diabetes Association (ADA) Scientific Sessions regarding its investigational treatment, amycretin.
Read more →
Novo Nordisk advances amycretin into phase 3 for weight management
June 12, 2025
Novo Nordisk has announced plans to advance subcutaneous and oral amycretin into phase 3 clinical development for weight management.
Read more →
Novo Nordisk unveils new semaglutide data at ADA scientific sessions
June 10, 2025
Novo Nordisk has announced that it will present new data from its portfolio in metabolic and cardiovascular health at the American Diabetes Association (ADA) 85th Scientific Sessions, scheduled to take place in Chicago from June 20 to June 23, 2025.
Read more →
Novo Nordisk announces leadership changes amid market challenges
May 16, 2025
Novo Nordisk has announced that Lars Fruergaard Jørgensen will step down as CEO, a decision made in mutual agreement with the company's Board.
Read more →
Novo Nordisk partners with Septerna for cardiometabolic disease treatments
May 14, 2025
Septerna, Inc. and Novo Nordisk have announced a global collaboration to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.
Read more →
Trending
The Weekly Newsletter
Sign-up for the Weekly Newsletter from EU Business Daily.